Product image of Mycophenolatmofetil Accord (Mycophenolate Mofetil) supplied by GNH India

Mycophenolatmofetil Accord

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Mycophenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Accord, is an immunosuppressant presented as an intravenous formulation for use in transplant patients. It is employed to reduce the risk of organ rejection by selectively inhibiting lymphocyte proliferation.
GNH India supplies Mycophenolatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate Mofetil is an antimetabolite immunosuppressant used in solid‑organ transplantation to prevent graft rejection.

  • Kidney transplantation: helps prevent acute and chronic rejection of the transplanted kidney.
  • Heart transplantation: reduces the incidence of early rejection episodes after cardiac graft.
  • Liver transplantation: maintains graft function and lowers rejection risk in hepatic recipients.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This enzyme is essential for de novo guanosine nucleotide synthesis in lymphocytes. By blocking IMPDH, the drug suppresses proliferation of T and B cells, thereby attenuating the immune response that leads to organ graft rejection.

Side Effects

Adverse reactions may occur with Mycophenolatmofetil Accord and are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may require supportive care.
  • Vomiting: occasional emesis after infusion.
  • Abdominal pain: crampy discomfort in the stomach area.
  • Headache: transient mild to moderate pain.
  • Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects

  • Leukopenia: significant reduction in white blood cells.
  • Anemia: decreased red blood cell count leading to fatigue.
  • Severe infections: opportunistic infections such as CMV or PCP.
  • Malignancy: heightened risk of post‑transplant lymphoproliferative disorders.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Progressive multifocal leukoencephalopathy: rare but serious brain infection.

Precautions & Warnings

Before initiating therapy with Mycophenolatmofetil Accord, several safety considerations should be observed.

  • Pregnancy: Category D – avoid use unless the potential benefit justifies the risk to the fetus.
  • Infection risk: monitor patients closely for signs of opportunistic infections.
  • Hematologic monitoring: perform regular complete blood counts to detect leukopenia or anemia.
  • Renal function: adjust dosing in patients with impaired renal clearance.
  • Drug interactions: review concomitant medications for potential additive immunosuppression.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Avoid Interactions

Mycophenolatmofetil Accord can interact with several agents, requiring careful management.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias.
  • Live vaccines: increased risk of vaccine‑derived infection.
  • Rituximab: combined immunosuppression heightens infection susceptibility.

Moderate Interactions (Monitor Closely)

  • Cyclosporine: may increase mycophenolate plasma concentrations.
  • Tacrolimus: concurrent use can elevate drug levels and toxicity.
  • Antacids containing aluminum or magnesium: may reduce oral absorption of mycophenolic acid.

Frequently Asked Questions

Mycophenolatmofetil Accord contains mycophenolate mofetil, an immunosuppressant used primarily to prevent rejection of transplanted organs such as kidneys, hearts, and livers. It works by dampening the immune response that can attack the graft, thereby improving transplant outcomes.

Mycophenolate mofetil is converted in the body to mycophenolic acid, which selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This enzyme is crucial for guanosine nucleotide synthesis in lymphocytes, so its inhibition blocks the proliferation of T and B cells, reducing immune‑mediated graft rejection.

The dosage of Mycophenolatmofetil Accord is determined by the prescribing physician based on the type of transplant, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional should set the exact dosing regimen.

Mycophenolatmofetil Accord is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism by targeting lymphocyte proliferation rather than T‑cell activation. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing toxicity.

The product should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Mycophenolatmofetil Accord is given intravenously under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescribing physician and nursing staff, following institutional protocols for sterile preparation and administration.

Serious risks include severe infections, leukopenia or anemia, hepatic toxicity, and rare but life‑threatening conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for blood counts, liver function, and signs of infection, and any concerning symptoms reported promptly.

Mycophenolatmofetil Accord is contraindicated in patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation. It should also be avoided in individuals with active, uncontrolled infections or in those receiving live vaccines, unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT